Fulcrum Therapeutics Approves Executive Retention Payments

Fulcrum Therapeutics, Inc. approved cash retention payments for its nine remaining full-time employees, including key executives Alex C. Sapir (President and CEO), Curtis Oltmans (Chief Legal Officer), and Alan Musso (CFO), following a previously disclosed restructuring plan. These payments are contingent upon a Change in Control or termination without Cause, provided transitional duties are met. Additionally, the company extended "Change in Control" benefits to all remaining employees at the Vice President level and above. Separately, Greg Tourangeau, Vice President, Finance, and principal accounting officer, will depart from his position by mutual agreement.